| Business Summary | | EPIX
Medical,
Inc.
is
engaged
in
the
development
of
targeted
contrast
agents
to
both
improve
the
capability
and
expand
the
use
of
magnetic
resonance
imaging
(MRI)
as
a
diagnostic
tool
for
a
variety
of
diseases.
The
Company's
principal
product
under
development,
MS-325,
is
an
injectable
intravascular
contrast
agent
designed
for
multiple
cardiovascular
imaging
applications,
including
peripheral
vascular
disease
and
coronary
artery
disease.
MS-325
is
a
small
molecule
that
produces
an
MRI
signal
by
containing
gadolinium,
a
highly
magnetically
active
element
used
for
enhancing
magnetic
resonance
images.
This
molecule
is
designed
with
the
Company's
proprietary
technology
to
bind
to
albumin,
a
common
blood
protein.
In
MS-325
images
using
standard
MRI
techniques,
the
blood
gives
off
a
strong
magnetic
signal
and
appears
bright
against
the
dark
background
of
surrounding
tissue. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | EPIX
is
a
development
stage
company,
engaged
in
the
development
of
targeted
contrast
agents
both
to
improve
the
capability
and
expand
the
use
of
magnetic
resonance
imaging
(MRI)
as
a
tool
for
diagnosing
human
diseases.
For
the
six
months
ended
6/01,
revenues
rose
6%
to
$3.9
million.
Net
loss
before
acct'g
change
rose
10%
to
$10.1
million.
Revenues
reflect
the
development
funding
terms
under
the
Schering
agreement.
Higher
loss
reflects
higher
clinical
trial
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Christopher Gabrieli, 41 Chairman | -- | -- | Michael Webb, 42 CEO,
Sec., Director | $379K | $48K | Stephen Knight, M.D., 40 Pres,
COO | 339K | -- | Randall Lauffer, Ph.D., 43 Director
and CSO | 257K | -- | Alan Carpenter, Ph.D., 48 Exec.
VP of R&D | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|